SOD1 and amyotrophic lateral sclerosis: This indicates that the incomplete knockdown of SOD1 and use of nanoengineered delivery tools may be reasonable and safe options for ALS treatment, offering new ideas for further clinical trials (Meijboom and Brown, 2022).